• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Optimization of the sequence of antigen loading and CD40-ligand-induced maturation of dendritic cells.

作者信息

Morse M A, Lyerly H K, Gilboa E, Thomas E, Nair S K

机构信息

Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA.

出版信息

Cancer Res. 1998 Jul 15;58(14):2965-8.

PMID:9679955
Abstract

Dendritic cells (DCs), matured by CD40-ligand (CD40L), undergo marked changes in their ability to process and present antigen, resulting in augmented lymphocyte stimulatory activity. We demonstrate that the form of the tumor antigen (peptide or genetic material) used to load the DCs dictates the required sequence of antigen loading and maturation for antitumor immunotherapy. Optimal stimulation of carcinoembryonic antigen (CEA)-specific CTLs by peptide-loaded DCs occurs when DCs from cancer patients are matured with CD40L before exposure to CEA peptide, whereas optimal stimulation by RNA-transfected DCs occurs when the DCs are loaded with CEA RNA before maturation with CD40L.

摘要

相似文献

1
Optimization of the sequence of antigen loading and CD40-ligand-induced maturation of dendritic cells.
Cancer Res. 1998 Jul 15;58(14):2965-8.
2
Appropriate timing of CD40 ligation for RNA-Pulsed DCs to induce antitumor immunity.用于RNA脉冲树突状细胞诱导抗肿瘤免疫的CD40连接的合适时机。
Scand J Immunol. 2008 Apr;67(4):385-91. doi: 10.1111/j.1365-3083.2008.02083.x. Epub 2008 Feb 14.
3
CD40 ligand is essential for generation of specific cytotoxic T cell responses in RNA-pulsed dendritic cell immunotherapy.CD40配体在RNA脉冲树突状细胞免疫疗法中对于产生特异性细胞毒性T细胞反应至关重要。
Surgery. 2003 Aug;134(2):300-5. doi: 10.1067/msy.2003.240.
4
Adenovirus-mediated CD40 ligand gene-engineered dendritic cells elicit enhanced CD8(+) cytotoxic T-cell activation and antitumor immunity.腺病毒介导的CD40配体基因工程树突状细胞引发增强的CD8(+)细胞毒性T细胞活化和抗肿瘤免疫。
Cancer Gene Ther. 2002 Feb;9(2):202-8. doi: 10.1038/sj.cgt.7700429.
5
Functional CD40 ligand expressed by human blood dendritic cells is up-regulated by CD40 ligation.人血液树突状细胞表达的功能性CD40配体通过CD40连接而被上调。
J Immunol. 1996 Nov 15;157(10):4363-70.
6
Concurrent delivery of tumor antigens and activation signals to dendritic cells by irradiated CD40 ligand-transfected tumor cells resulted in efficient activation of specific CD8+ T cells.经辐照的转染了CD40配体的肿瘤细胞将肿瘤抗原和激活信号同时传递给树突状细胞，从而有效激活了特异性CD8⁺T细胞。
Cancer Gene Ther. 2004 Feb;11(2):135-47. doi: 10.1038/sj.cgt.7700663.
7
Blood dendritic cells generated with Flt3 ligand and CD40 ligand prime CD8+ T cells efficiently in cancer patients.使用Flt3配体和CD40配体生成的血液树突状细胞能有效地激活癌症患者的CD8+T细胞。
J Immunother. 2006 Sep-Oct;29(5):499-511. doi: 10.1097/01.cji.0000211299.29632.8c.
8
Streptococcal preparation OK-432 promotes the capacity of dendritic cells (DCs) to prime carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocyte responses induced with genetically modified DCs that express CEA.链球菌制剂OK-432可增强树突状细胞（DC）启动由表达癌胚抗原（CEA）的基因修饰DC诱导的CEA特异性细胞毒性T淋巴细胞反应的能力。
Int J Oncol. 2008 Feb;32(2):459-66.
9
Double-stranded RNA stimulation or CD40 ligation of monocyte-derived dendritic cells as models to study their activation and maturation process.以双链RNA刺激或CD40连接单核细胞衍生的树突状细胞作为模型来研究它们的激活和成熟过程。
Eur Cytokine Netw. 2004 Apr-Jun;15(2):126-34.
10
The infection of human dendritic cells with recombinant avipox vectors expressing a costimulatory molecule transgene (CD80) to enhance the activation of antigen-specific cytolytic T cells.用表达共刺激分子转基因（CD80）的重组禽痘病毒载体感染人树突状细胞，以增强抗原特异性细胞毒性T细胞的激活。
Cancer Res. 2001 Oct 15;61(20):7568-76.

引用本文的文献

1
mRNA-based therapeutics--developing a new class of drugs.mRNA 疗法——开发一类新药。
Nat Rev Drug Discov. 2014 Oct;13(10):759-80. doi: 10.1038/nrd4278. Epub 2014 Sep 19.
2
T-cell-independent antitumor effects of CD40 ligation.CD40 配体的 T 细胞非依赖性抗肿瘤作用。
Int Rev Immunol. 2012 Aug;31(4):267-78. doi: 10.3109/08830185.2012.698337.
3
The Tat-conjugated N-terminal region of mucin antigen 1 (MUC1) induces protective immunity against MUC1-expressing tumours.黏蛋白抗原1（MUC1）的Tat缀合N端区域可诱导针对表达MUC1的肿瘤的保护性免疫。
Clin Exp Immunol. 2009 Nov;158(2):174-85. doi: 10.1111/j.1365-2249.2009.03997.x. Epub 2009 Jul 17.
4
Protective anti-tumour immune responses by murine dendritic cells pulsed with recombinant Tat-carcinoembryonic antigen derived from Escherichia coli.用源自大肠杆菌的重组Tat-癌胚抗原脉冲处理的小鼠树突状细胞产生的保护性抗肿瘤免疫反应。
Clin Exp Immunol. 2009 Jul;157(1):128-38. doi: 10.1111/j.1365-2249.2009.03943.x.
5
Generation in vivo of peptide-specific cytotoxic T cells and presence of regulatory T cells during vaccination with hTERT (class I and II) peptide-pulsed DCs.在用人端粒酶逆转录酶（hTERT，I类和II类）肽脉冲树突状细胞（DCs）进行疫苗接种期间，体内肽特异性细胞毒性T细胞的产生及调节性T细胞的存在。
J Transl Med. 2009 Mar 19;7:18. doi: 10.1186/1479-5876-7-18.
6
The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients.抗血管内皮生长因子（VEGF）疗法对癌症患者未成熟髓样细胞和树突状细胞的影响。
Cancer Immunol Immunother. 2008 Aug;57(8):1115-24. doi: 10.1007/s00262-007-0441-x. Epub 2008 Jan 10.
7
Phase I/II study of treatment with matured dendritic cells with or without low dose IL-2 in patients with disseminated melanoma.采用成熟树突状细胞联合或不联合低剂量白细胞介素-2治疗播散性黑色素瘤患者的I/II期研究。
Cancer Immunol Immunother. 2008 Jul;57(7):1039-51. doi: 10.1007/s00262-007-0435-8.
8
Dendritic cell preactivation impairs MHC class II presentation of vaccines and endogenous viral antigens.树突状细胞预激活会损害疫苗和内源性病毒抗原的MHC II类呈递。
Proc Natl Acad Sci U S A. 2007 Nov 6;104(45):17753-8. doi: 10.1073/pnas.0708622104. Epub 2007 Oct 31.
9
DC-based cancer vaccines.基于树突状细胞的癌症疫苗。
J Clin Invest. 2007 May;117(5):1195-203. doi: 10.1172/JCI31205.
10
Phenotypic and functional characteristics of dendritic cells derived from human peripheral blood monocytes.源自人外周血单核细胞的树突状细胞的表型和功能特征。
J Zhejiang Univ Sci B. 2005 Dec;6(12):1176-81. doi: 10.1631/jzus.2005.B1176.